Clinical characteristics and outcomes of cancer patients with COVID-19

J Med Virol. 2020 Oct;92(10):2067-2073. doi: 10.1002/jmv.25972. Epub 2020 Jun 2.

Abstract

This retrospective study aimed to analysis clinical characteristics and outcomes of cancer patients with novel coronavirus disease-19 (COVID-19). Medical records, laboratory results and radiologic findings of 52 cancer patients with COVID-19 were collected, clinical characteristics and outcomes were summarized. A total of 52 cancer patients with COVID-19 were included. Median age of 52 cancer patients with COVID-19 was 63 years (34-98). Thirty-three (63.5%) patients were mild and 19 (36.5%) were severe/critical. Lung cancer was the most frequent cancer type (10, 19.2%). The common symptoms were as follows: fever (25%), dry cough (17.3%), chest distress (11.5%), and fatigue (9.6%). There were 33 (63.5%) patients had comorbidities, the most common symptom was hypertension (17, 51.5%). Twenty-six (78.8%) patients developed pneumonia on admission. Lymphocytes (0.6 × 109/L) decreased in both mild and severe/critical patients. Median levels of D-dimer, C-reactive protein, procalcitonin, and lactate dehydrogenase were 2.8 mg/L, 70.5 mg/L, 0.3 ng/mL, and 318 U/L, respectively, which increased significantly in severe/critical patients compared with the mild patients. Interleukin-6 (12.6 pg/mL) increased in both mild and severe/critical patients, there was a significant difference between them. Complications were observed in 29 (55.8%) patients, such as liver injury (19, 36.5%), acute respiratory distress syndrome (9, 17.3%), sepsis (8, 15.4%), myocardial injury (8, 15.4%), renal insufficiency (4, 7.7%), and multiple organ dysfunction syndrome (3, 5.8%). Eleven (21.2%) patients with cancer died. The infection rate of severe acute respiratory syndrome coronavirus 2 in patients with cancer was higher than the general population, cancer patients with COVID-19 showed deteriorating conditions and poor outcomes.

Keywords: COVID-19; SARS-CoV-2; cancer; infection.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • COVID-19 / diagnostic imaging
  • COVID-19 / mortality
  • COVID-19 / physiopathology*
  • COVID-19 / therapy
  • China
  • Comorbidity
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / mortality
  • Coronary Disease / physiopathology*
  • Coronary Disease / therapy
  • Cough / physiopathology
  • Diabetes Mellitus / diagnostic imaging
  • Diabetes Mellitus / mortality
  • Diabetes Mellitus / physiopathology*
  • Diabetes Mellitus / therapy
  • Fatigue / physiopathology
  • Female
  • Fever / physiopathology
  • Humans
  • Hypertension / diagnostic imaging
  • Hypertension / mortality
  • Hypertension / physiopathology*
  • Hypertension / therapy
  • Immunoglobulins, Intravenous / therapeutic use
  • Lymphocytes / pathology
  • Lymphocytes / virology
  • Male
  • Middle Aged
  • Neoplasms / diagnostic imaging
  • Neoplasms / mortality
  • Neoplasms / physiopathology*
  • Neoplasms / therapy
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / pathogenicity
  • Severity of Illness Index
  • Survival Analysis
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Antineoplastic Agents
  • Antiviral Agents
  • Immunoglobulins, Intravenous